295 related articles for article (PubMed ID: 26152702)
41. [Acute toxicity of high doses of methotrexate in treatment of ALL in children: a case study].
Periáñez-Párraga L; Pérez-Rodríguez O; do Pazo-Oubiña F; Crespí-Monjo M
Farm Hosp; 2009; 33(3):172-3. PubMed ID: 19712601
[No Abstract] [Full Text] [Related]
42. Early, empiric high-dose leucovorin rescue in lymphoma patients treated with sequential doses of high-dose methotrexate.
Barreto JN; Peterson KT; Barreto EF; Mara KC; Dierkhising RA; Leung N; Witzig TE; Thompson CA
Support Care Cancer; 2021 Sep; 29(9):5293-5301. PubMed ID: 33661366
[TBL] [Abstract][Full Text] [Related]
43. A single center retrospective analysis of a protocol for high-dose methotrexate and leucovorin rescue administration.
Cerminara Z; Duffy A; Nishioka J; Trovato J; Gilmore S
J Oncol Pharm Pract; 2019 Jan; 25(1):76-84. PubMed ID: 28942720
[TBL] [Abstract][Full Text] [Related]
44. Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin-tazobactam.
Burgess LD; Drew RH
Pharmacotherapy; 2014 Jul; 34(7):670-6. PubMed ID: 24855041
[TBL] [Abstract][Full Text] [Related]
45. High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series.
Blay JY; Conroy T; Chevreau C; Thyss A; Quesnel N; Eghbali H; Bouabdallah R; Coiffier B; Wagner JP; Le Mevel A; Dramais-Marcel D; Baumelou E; Chauvin F; Biron P
J Clin Oncol; 1998 Mar; 16(3):864-71. PubMed ID: 9508167
[TBL] [Abstract][Full Text] [Related]
46. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma.
Widemann BC; Balis FM; Kempf-Bielack B; Bielack S; Pratt CB; Ferrari S; Bacci G; Craft AW; Adamson PC
Cancer; 2004 May; 100(10):2222-32. PubMed ID: 15139068
[TBL] [Abstract][Full Text] [Related]
47. High dose intravenous colistin methanesulfonate therapy is associated with high rates of nephrotoxicity; a prospective cohort study from Saudi Arabia.
Omrani AS; Alfahad WA; Shoukri MM; Baadani AM; Aldalbahi S; Almitwazi AA; Albarrak AM
Ann Clin Microbiol Antimicrob; 2015 Jan; 14():3. PubMed ID: 25591721
[TBL] [Abstract][Full Text] [Related]
48. Statistical analysis of relation between plasma methotrexate concentration and toxicity in high-dose methotrexate therapy of childhood nonHodgkin lymphoma.
Tsurusawa M; Gosho M; Mori T; Mitsui T; Sunami S; Kobayashi R; Fukano R; Tanaka F; Fujita N; Inada H; Koh K; Takimoto T; Saito A; Fujimoto J; Nakazawa A; Horibe K;
Pediatr Blood Cancer; 2015 Feb; 62(2):279-284. PubMed ID: 25359701
[TBL] [Abstract][Full Text] [Related]
49. Genetic polymorphisms and clinical parameters associated with renal toxicity in Thai hematologic malignancy patients receiving high dose methotrexate.
Pitakkitnukun P; Pongpitakmetha T; Suttichet TB; Sukkummee W; Chariyavilaskul P; Polprasert C
Sci Rep; 2024 Apr; 14(1):9695. PubMed ID: 38678107
[TBL] [Abstract][Full Text] [Related]
50. Risk factors for acute kidney injury in adult patients receiving vancomycin.
Cappelletty D; Jablonski A; Jung R
Clin Drug Investig; 2014 Mar; 34(3):189-93. PubMed ID: 24385282
[TBL] [Abstract][Full Text] [Related]
51. High-dose methotrexate for primary CNS lymphoma in the elderly.
Ng S; Rosenthal MA; Ashley D; Cher L
Neuro Oncol; 2000 Jan; 2(1):40-4. PubMed ID: 11302253
[TBL] [Abstract][Full Text] [Related]
52. Early recognition of patients with decreased methotrexate clearance following high-dose methotrexate infusion therapy.
Ikeda H; Kihira K; Kuwata N; Arai S; Kimura Y; Miyake K; Kitaura T; Fujimura K; Kuramoto A; Fukuchi H
Hiroshima J Med Sci; 1996 Jun; 45(2):57-62. PubMed ID: 8810132
[TBL] [Abstract][Full Text] [Related]
53. Co-administration of proton pump inhibitors ameliorates nephrotoxicity in patients receiving chemotherapy with cisplatin and fluorouracil: a retrospective cohort study.
Ikemura K; Oshima K; Enokiya T; Okamoto A; Oda H; Mizuno T; Ishinaga H; Muraki Y; Iwamoto T; Takeuchi K; Katayama N; Okuda M
Cancer Chemother Pharmacol; 2017 May; 79(5):943-949. PubMed ID: 28364288
[TBL] [Abstract][Full Text] [Related]
54. Concomitant use of low-dose methotrexate and NSAIDs and the risk of serious adverse events among patients with rheumatoid arthritis.
Svanström H; Lund M; Melbye M; Pasternak B
Pharmacoepidemiol Drug Saf; 2018 Aug; 27(8):885-893. PubMed ID: 29797447
[TBL] [Abstract][Full Text] [Related]
55. Risk factors for high-dose methotrexate associated toxicities in patients with primary central nervous system lymphoma.
Sun K; Tao H; Ding T; Li Z; Qiu X; Zhong M; Wu Z
J Clin Pharm Ther; 2022 Dec; 47(12):2196-2204. PubMed ID: 36259502
[TBL] [Abstract][Full Text] [Related]
56. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial.
Ferreri AJ; Reni M; Foppoli M; Martelli M; Pangalis GA; Frezzato M; Cabras MG; Fabbri A; Corazzelli G; Ilariucci F; Rossi G; Soffietti R; Stelitano C; Vallisa D; Zaja F; Zoppegno L; Aondio GM; Avvisati G; Balzarotti M; Brandes AA; Fajardo J; Gomez H; Guarini A; Pinotti G; Rigacci L; Uhlmann C; Picozzi P; Vezzulli P; Ponzoni M; Zucca E; Caligaris-Cappio F; Cavalli F;
Lancet; 2009 Oct; 374(9700):1512-20. PubMed ID: 19767089
[TBL] [Abstract][Full Text] [Related]
57. High-dose intravenous vancomycin therapy and the risk of nephrotoxicity.
Rostas SE; Kubiak DW; Calderwood MS
Clin Ther; 2014 Jul; 36(7):1098-101. PubMed ID: 24931573
[TBL] [Abstract][Full Text] [Related]
58. Association between colistin dose and development of nephrotoxicity.
Lee YJ; Wi YM; Kwon YJ; Kim SR; Chang SH; Cho S
Crit Care Med; 2015 Jun; 43(6):1187-93. PubMed ID: 25756417
[TBL] [Abstract][Full Text] [Related]
59. Glucarpidase (carboxypeptidase g2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy.
Schwartz S; Borner K; Müller K; Martus P; Fischer L; Korfel A; Auton T; Thiel E
Oncologist; 2007 Nov; 12(11):1299-308. PubMed ID: 18055849
[TBL] [Abstract][Full Text] [Related]
60. Low prevalence of high-dose methotrexate nephropathy in patients with malignancy.
Mashhadi MA; Kaykhaei MA; Sanadgol H
Iran J Kidney Dis; 2012 Mar; 6(2):105-9. PubMed ID: 22388607
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
